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Abstract
Coagulation activation and venous thromboembolism (VTE) are hallmarks of cancer; how-
ever, there is an unmet need of improved biomarkers for individualized anticoagulant treat-
ment. The present sub-study of the RASTEN trial was designed to explore the role of
coagulation biomarkers in predicting VTE risk and outcome in a homogenous cancer patient
population. RASTEN is a multicenter, randomized phase-3 trial investigating the survival
effect of low molecular weight heparin enoxaparin when added to standard treatment in
newly diagnosed small cell lung cancer (SCLC) patients. Plasma collected at baseline, dur-
ing treatment, and at follow-up was used in this ad hoc sub-study (N = 242). Systemic coag-
ulation was assessed using four assays reflecting various facets of the coagulation system:
Total tissue factor (TF); extracellular vesicle associated TF (EV-TF); procoagulant phospho-
lipids (PPL); and thrombin generation (TG). We found small variations of biomarker levels
between baseline, during treatment and at follow-up, and appeared independent on low
molecular weight heparin treatment. Overall, none of the measured biomarkers at any time-
point did significantly associate with VTE incidence, although increased total TF at baseline
showed significant association in control patients not receiving low molecular weight heparin
(P = 0.03). Increased TG-Peak was significantly associated with decreased overall survival
(OS; P = 0.03), especially in patients with extensive disease. Low baseline EV-TF predicted
a worse survival in the low molecular weight heparin as compared with the control group
(HR 1.42; 95% CI 1.04–1.95; P = 0.03; P for interaction = 0.12). We conclude that the value
of the analyzed coagulation biomarkers for the prediction of VTE risk was very limited in
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SCLC patients. The associations between TG-Peak and EV-TF with patient survival and
response to low molecular weight heparin therapy, respectively, warrant further studies on
the role of coagulation activation in SCLC aggressiveness.
Introduction
Oncogene activation and the tumor microenvironment induce a hypercoagulable state and an
increased risk of venous thromboembolism (VTE) [1–3], which are hallmarks in malignancy
and major contributors to cancer-associated mortality and morbidity [4–6]. It is important to
find predictive biomarkers to identify patients who may benefit from prophylactic anticoagu-
lant treatment, not only in terms of preventing thrombotic events but also to improve survival.
Thrombin is a key factor in coagulation activation [7], and its generation has been widely stud-
ied to unravel the mechanisms of cancer-associated VTE. Thrombin generation (TG), as deter-
mined by the calibrated automated thrombogram (CAT) assay, has recently gained interest as a
biomarker of disease aggressiveness as well as VTE risk in cancer [8,9]. Cancer-associated hyper-
coagulability may in part be explained by the activation of tissue factor (TF), which is the main ini-
tiator of coagulation [6,10,11]. Tumor TF expression has been correlated to increased risk of VTE
and metastatic disease, indicating that TF has direct clinical implications both in tumor progres-
sion and VTE development [12]. TF can be released from tumor cells in the form of extracellular
vesicles (EV-TF) or as an alternatively-spliced from lacking the transmembrane domain [13,14].
Previous studies in small patient cohorts have found some evidence for a correlation of EV-TF
activity with VTE in pancreatic cancer but not in other forms of cancer, including gastric, brain,
lung and ovarian cancers [15–18]. Procoagulant phospholipids (PPL) represent another impor-
tant factor for coagulation activity with potential to predict VTE risk. PPL are exposed on the
outer membrane leaflet of EVs and provide a negatively charged surface for the decryption of TF,
assembly of coagulation complexes, and thrombin formation [19,20].
Apart from its antithrombotic properties, pre-clinical evidence indicates that heparin and
low molecular weight heparin (LMWH) have direct tumor-inhibiting effects via e.g. inhibition
of angiogenesis and metastasis [21–23]. The potential antitumoral effects have been further
investigated in the clinical setting. A few early studies showed survival benefits when anticoag-
ulants were administered prophylactically to cancer patients, particularly in small cell lung
cancer (SCLC) [24–25]. However, more recent randomized trials have not been able to show
survival advantage with LMWH in lung cancer [26,27]. This includes a phase III trial in which
a homogenous population of SCLC patients were randomized to receive standard treatment
with or without the addition of LMWH (RASTEN) [27].
In the present sub-study of the RASTEN trial, our aim was to directly compare the potential
utility of coagulation-related biomarkers for the prediction of VTE risk in SCLC patients using
a comprehensive approach that includes total TF, EV-TF, TG, and PPL. Also, we addressed
correlations between coagulation biomarkers and patient survival to elucidate the potential
role of coagulation activation in SCLC aggressiveness.
Materials and methods
RASTEN clinical trial
A full description of the study design has been reported previously [27]. In brief, RASTEN
(ClinicalTrials.gov: NCT00717938) is an international, prospective, open-label trial in patients
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with newly diagnosed SCLC of all stages, WHO performance status 0 to 3 and standard coagu-
lation parameters within normal ranges. Patients were randomized 1:1 between a control arm
receiving standard treatment and an intervention arm receiving standard treatment with the
addition of LMWH enoxaparin given at 1 mg/kg as daily subcutaneous injections, starting on
day 1 of chemotherapy and continued throughout the duration of the chemotherapy regimen.
Standard therapy included a platinum compound and a topoisomerase inhibitor administered
for 4–6 cycles according to local guidelines. Radiotherapy was given depending on disease
extent and response to chemotherapy, following local protocols. Written, informed consent
was obtained from all study participants. The study was carried out according to the ICH/GCP
guidelines, in agreement with the Helsinki declaration and with approval from the regional
ethics committee at Lund University, Sweden.
Patient selection and plasma sampling
Plasma was collected at baseline, prior to the third chemotherapy cycle and at a 2 months’ fol-
low-up visit according to the study protocol. Blood samples were collected in sodium citrate
and EDTA tubes, centrifuged at 2000 x g for 15 min at room temperature (RT) and stored in a
-80˚C freezer. The present biomarker cohort was established at the cut-off date of November
1st 2013, consisting of the first consecutive 292 patients.
Total tissue factor
Total TF was determined in patient EDTA-plasma at baseline using the Proseek Multiplex
CVD96x96 panel (Olink Bioscience, Uppsala, Sweden), as previously described [28]. The assay
is based on proximity extension assay (PEA) technology, which provides high sensitivity and
specificity based on the binding of oligonucleotide-labeled antibody probe pairs to their spe-
cific target protein, generating a PCR-amplified DNA template, which is proportional to the
initial antigen concentration as quantified by real-time qPCR. Four internal and three negative
controls were used to calculate the lower limit of detection (LOD) for each protein.
Tissue factor activity associated with extracellular vesicles
EV-TF activity was determined as described previously [29]. Briefly, EVs were pelleted by cen-
trifugation at 20 000 x g for 15 min and mixed with human anti-TF-antibody (HTF-1; BD
Pharmingen, CA, USA) or mouse control IgG antibody (BD Pharmingen, CA, USA) at RT for
15 min, followed by addition of coagulation factors VIIa (10 nM) and X (300 nM) as well as
CaCl2 (10 mM) in a 96-well plate. A standard curve of recombinant human TF Innovin (0–55
pg/ml, Siemens, Germany) was applied to the plate, which was then incubated for 2 h at 37˚C.
FXa generation was terminated by EDTA (25 nM), after which Pefachrome FXa (Pentapharm,
Switzerland) substrate was added for 15 min at RT, and absorbance was measured at 405 nm
using a VERSAmax microplate reader (Molecular Devices Corp., CA, USA). TF-dependent
FXa generation was determined by subtracting the obtained values in hTF-1 wells from values
in control IgG wells.
Procoagulant phospholipid assay
PPL activity was measured per manufacturer’s instructions using Procoag-PPL (STAGO inc.,
France), which is a FXa-based clotting method that utilizes phospholipid-depleted plasma to
assess the activity of PPL in samples. Briefly, 25 μL sample plasma was added to a cuvette con-
taining 25 μL human phospholipid-depleted plasma, and incubated for 2 min at 37˚C. Subse-
quently, pre-heated XACT-reagent (STAGO inc., France) containing FXa and Ca2+ was
Biomarkers of venous thromboembolism in cancer
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added, and clotting time was determined based on the motion of a spherical steal ball. Notably,
a short clotting time indicates an increased PPL activity.
Thrombin generation assay
The TG capacity was determined using a modified version of the calibrated automated throm-
bogram assay [30]. Since LMWH interferes with the assay, analyses at cycle 3 included patients
only in the control arm. Briefly, 65 μL sodium citrate plasma was mixed with 20 μL of either
trigger (1 pM TF and 4 μM phospholipids; PPPlow, Thrombinoscope BV, Netherlands) or cali-
brator solution. Samples were heated to 37˚C and TG was initiated using 20 μl pre-heated
FluCa buffer containing a fluorescence substrate and CaCl2 (Thrombinoscope BV, Nether-
lands). Fluorescence intensity was read over 45 min with a 390/460 excitation/emission filter
set and TG curves were generated using Thrombinoscope software version 5.0 (Thrombino-
scope BV, Netherlands). Three established TG parameters were validated through statistical
analyses; endogenous thrombin potential (TG-ETP), peak height (TG-Peak), and time to peak
(TG-ttPeak).
Statistical analyses
The statistics programs SPSS v22, Stata 15.1, and R 3.3.0 were used for data analysis and graph-
ics. Correlation between pairs of biomarkers was quantified using Spearman’s rank correlation
coefficient and visualized in a heat map using the R-package ggplot2. Non-parametric tests
were used for comparisons of biomarker levels in different subgroups (Mann-Whitney test)
and over time (Wilcoxon matched-pairs signed rank test). The Kaplan-Meier method was
used to estimate survival probabilities and the evidence for difference in survival between
groups formed by categorization of a biomarker was evaluated using a logrank test or, for
three ordered categories, a logrank test for trend. Cox regression was used to quantify the cor-
responding biomarker effects on survival as hazard ratios. A multivariable Cox model with an
interaction term was used to test for differential treatment effect in subgroups based on a bio-
marker. Time zero was defined as date of diagnosis in survival analyses including biomarkers
measured only at baseline. For analyses at later time points, time zero was shifted to the corre-
sponding sampling date (landmark analysis). The P-values in this exploratory study have not
been adjusted for multiple testing. The reader should keep this in mind when interpreting the
level of evidence for each test performed. The P-values should not be compared to the often
used cut-off 5%, but rather be seen as continuous measures of evidence against the null
hypotheses.
Results
Study population
By November 2013, blood samples had been collected for the first 292 patients enrolled in the
RASTEN trial (Fig 1). Eight patients were excluded as further investigations showed other his-
tology than SCLC, and six patients did not fulfil the inclusion criteria. Samples were unavail-
able in 18 cases. For each of the assays, a varying number of samples were excluded due to
insufficient volumes or hemolysis. In total, blood samples from 242 patients were included in
the present coagulation biomarker cohort, 115 in the LMWH and 127 in the control arm.
Baseline characteristics were comparable between both study arms (Table 1). Median follow-
up was 276 days for patients still alive. Median overall survival (OS) was 9.9 and 10.9 months
(P = 0.08), with 1-year survival rates of 41% and 45% in the LMWH and control arms,
Biomarkers of venous thromboembolism in cancer
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respectively. Fifteen patients developed VTE, of which twelve and three patients were in the
control and LMWH arm, respectively.
Coagulation biomarkers depending on disease extent and LMWH
treatment
As expected in this randomized trial, all coagulation biomarkers were comparable in the con-
trol and LMWH treatment arms at baseline (Table 2). TG parameters, PPL activity, and
EV-TF showed small variations between baseline, during treatment and at follow-up, and
appeared independent on LMWH treatment (Table 2). Baseline EV-TF, but none of the other
biomarkers, was significantly higher in patients with ED as compared with LD (P = 0.04) (S1
Table). The distribution of EV-TF levels was particularly skewed with a large proportion of
PPL assay 
Poor sample quality 
(N=24) 
Analysis performed 
(N=236) 
TG assay 
Poor sample quality 
(N=27) 
Analysis performed 
(N=233) 
Included in any assay 
(N=242) 
Poor sample quality 
(N=25) 
Analysis performed 
(N=235) 
EV-TF assay Total TF assay 
Analysis performed 
(N=226) 
Poor sample quality 
(N=34) 
Assessed for eligibility 
(N=292) 
Available for analysis 
(N=260) 
 
Excluded (N=32) 
- Inclusion criteria not met (N=14) 
- Sample not available (N=18) 
Fig 1. Consort diagram of the study population.
https://doi.org/10.1371/journal.pone.0207387.g001
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samples below or near the detection limit. Hence, the patient group was dichotomized accord-
ing to the 75th percentile, representative of an EV-TF cut-off value of 0.32 pg/ml, which
revealed that 74% in the upper quartile had ED.
Correlations between coagulation biomarkers
Expectedly, the strongest correlations were seen between TG-Peak, TG-ETP and TG-ttPeak.
There were moderate correlations between the various TG parameters and PPL, while total TF
and EV-TF showed weak correlations to other biomarkers (Fig 2).
Coagulation biomarkers and VTE incidence
In the total patient population, baseline TF was associated with VTE incidence with borderline
significance (HR 2.8; P = 0.07). In the control arm, patients that eventually were diagnosed
with VTE had a small but significantly increased TF level (Table 3). EV-TF, TG parameters
and PPL did not show any association with VTE risk.
Coagulation biomarkers and patient outcome
We next addressed potential associations between baseline values of each coagulation bio-
marker and patient survival. A significant association was found between increasing TG-Peak
Table 1. Baseline characteristics of the study population.
LMWH
N = 115
Control
N = 127
Age, years
Mean ± SD 66 ± 8.1 67 ± 8.7
Gender, N (%)
Female 64 (56) 72 (57)
Male 51 (44) 55 (43)
Performance status, N (%)
0–1 81 (70) 91 (72)
2–3 34 (30) 36 (28)
Disease stage, N (%)
Limited 47 (41) 52 (41)
Extensive 68 (59) 75 (59)
Biochemistry, median (IQR)
Hemoglobin, g/L 134 (122–144) 133 (122–141)
Leukocyte count, x109/L 9.4 (7.3–12.2) 9.6 (7.0–12.8)
Platelet count, x109/L 336 (263–445) 309 (257–419)
Sodium, mmol/L 138 (135–140) 138 (134–141)
Potassium, mmol/L 4.1 (3.9–4.4) 4.3 (4.0–4.5)
Serum creatinine, μmol/L 65 (56–73) 66 (55–79)
aPTT, s 32 (28–36) 32 (28–35)
Overall survival
Median, months 9.9 10.9
12 months, % (95% CI) 41 (32–50) 45 (36–53)
VTE events, N (%) 3 (3) 12 (9)
SD = Standard deviation; IQR = Interquartile range; aPTT = Activated partial thromboplastin time; VTE = Venous
thromboembolism.
https://doi.org/10.1371/journal.pone.0207387.t001
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levels and decreased OS (P = 0.03; Fig 3 and Table 4), and this effect was stronger for patients
with ED (P = 0.01). For EV-TF, there was a trend towards an association between high levels
and decreased OS (P = 0.08; Table 4).
Coagulation biomarkers and effect of LMWH treatment
We next investigated the potential of coagulation parameters to predict the treatment effect of
LMWH. Notably, low baseline EV-TF predicted a decreased OS survival in patients receiving
the addition of LMWH as compared with control patients receiving chemotherapy only (HR
1.42; 95% confidence interval (CI) 1.04–1.95; P = 0.03). The P for interaction between baseline
EV-TF and survival effect of LMWH was 0.12 and 0.06 for OS with full and 1-year follow-up,
respectively, and the effect was specifically seen in patients with ED (Fig 4 and S1 Fig).
Discussion
The RASTEN study is the largest trial on the survival effect of LMWH in a patient population
with a homogenous tumor histology, SCLC [27]. The present ad hoc RASTEN sub-study
Table 2. Biomarkers at baseline, prior to cycle 3 and at 2 months’ follow up, for all patients and by treatment arm.
All patients LMWH arm Control arm
Median (IQR) N Median (IQR) N Median (IQR) N P-valuea (LMWH vs. Control arm)
EV-TF (pg/ml)
Baseline 0.19 (0.08–0.32) 235 0.21 (0.08–0.32) 110 0.18 (0.06–0.32) 125 0.43
Cycle 3 0.19 (0.09–0.31) 193 0.20 (0.10–0.30) 94 0.19 (0.08–0.32) 99 0.99
Follow up 0.15 (0.07–0.26) 130 0.13 (0.08–0.25) 65 0.16 (0.05–0.28) 65 0.75
TG-Peak (nM)
Baseline 219 (175–263) 233 227 (171–268) 111 218 (176–262) 122 0.73
Cycle 3b - - 264 (203–351)�� 98 -
Follow up 259 (187–337)�� 115 277 (195–340)� 61 252 (168–332)� 54 0.51
TG-ttPeak (min)
Baseline 9.8 (8.5–11.3) 233 9.8 (8.7–11.2) 111 9.9 (8.3–11.6) 122 0.93
Cycle 3b - - 9.2 (8.0–10.5)� 98 -
Follow up 9.7 (8.3–11.2) 115 9.7 (8.0–10.9) 61 9.6 (8.5–12.3) 54 0.59
TG-ETP (nM�min)
Baseline 1244 (1083–1403) 233 1264 (1116–1408) 111 1231 (1061–1403) 122 0.57
Cycle 3b - - 1424 (1151–1662)�� 98 -
Follow up 1415(1189–1703)�� 114 1345 (1183–1640)� 61 1482 (1175–1792)�� 53 0.32
PPL (sec)
Baseline 34.2 (28.5–40.0) 236 34.3 (28.2–39.9) 114 34.2 (28.5–40.2) 122 0.76
Cycle 3 35.3 (28.0–41.3) 195 35.0 (26.2–41.5) 96 35.3 (29.2–39.2) 99 0.92
Follow up 36.9 (30.0–45.9)� 120 36.2 (29.7–45.9)� 63 37.0 (32.0–45.9) 57 0.72
Total TF (a.u.)
Baseline 4.8 (4.6–5.1) 226 4.8 (4.6–5.1) 109 4.8 (4.6–5.2) 117 0.49
IQR = Interquartile range; EV-TF = Tissue factor associated with extracellular vesicles; TG = Thrombin generation; ttPeak = Time to peak; ETP = Endogenous
thrombin potential; PPL = Procoagulant phospholipids; TF = Tissue factor; a.u. = Arbitrary units. Changes in biomarker levels from baseline, using Wilcoxon matched-
pair signed rank test, noted as:
� unadjusted P<0.05
�� unadjusted P<0.001.
aComparison of biomarker levels based on treatment arms using Mann-Whitney test.
bLMWH interferes with TG assay, and the results at cycle 3 are only reported for the control arm.
https://doi.org/10.1371/journal.pone.0207387.t002
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investigated a potential role of biomarkers that reflect various facets of systemic coagulation
activity in the prediction of VTE risk and survival in a well-defined patient population enrolled
in a clinical trial. Several retrospective studies have investigated potential associations between
levels of EV-TF and VTE in e.g. pancreatic, gastric, lung, brain and ovarian cancer [15–18].
Whereas no such correlations have been found in other cancers, the results with pancreatic
cancer are conflicting; Thaler et al. [16] did not find any such association in a cohort of 43
patients, whereas Khorana et al. reported an association in a cohort encompassing 10 patients
[15]. The findings of the present study, showing no association between EV-TF and VTE in
SCLC lend further support to the limited value of EV-TF to predict VTE risk in cancer
patients.
The Vienna Cancer and Thrombosis Study (CATS) and the HYPERCAN study proposed
TG as a marker of the hypercoagulable profile in patients with cancer [8, 9]. However, both
studies encompass patients with mixed cancer diagnoses. In our study, with a homogenous
1 0.68**
1
−0.57**
−0.22**
1
−0.28**
−0.34**
0.44**
1
−0.16
−0.18*
0.03
0.25**
1
−0.15*
−0.36
−0.002
0.24**
0.22*
1
TG−PEAK
TG−ETP
TG−ttPEAK
PPL
EV−TF
Total TF
TG
−P
EA
K
TG
−E
TP
TG
−t
tP
EA
K
PP
L
EV
−T
F
To
ta
l T
F
−1.0 −0.5 0.0 0.5 1.0
Spearman
Correlation
*
Fig 2. Heat map of biomarker correlations at baseline. TF = Tissue factor; EV-TF = Tissue factor associated with
extracellular vesicles; PPL = Procoagulant phospholipids; TG = Thrombin generation; ttPeak = Time to peak;
ETP = Endogenous thrombin potential. Please note, TG-ttPeak and PPL are inversely correlated to procoagulant activity,
whereas all other biomarkers are positively correlated. � P<0.05; �� P<0.001.
https://doi.org/10.1371/journal.pone.0207387.g002
Biomarkers of venous thromboembolism in cancer
PLOS ONE | https://doi.org/10.1371/journal.pone.0207387 November 9, 2018 8 / 14
trial population, none of the TG parameters predicted VTE risk. These inconsistencies may
relate to insufficient standardization of the assays used, but probably also reflect the complexity
of the coagulation system in malignancy, e.g. it remains unclear how key regulatory factors,
including antithrombin and tissue factor pathway inhibitor-1, either soluble or EV-associated,
contribute to the overall coagulation status in cancer patients.
Table 3. Coagulation biomarkers at baseline vs VTE incidence by treatment arm.
Control
Median (IQR)
LMWH
Median (IQR)
No VTE
N = 115
VTE
N = 12
P-Value a No VTE
N = 112
VTEb
N = 3
P-Value a
EV-TF (pg/ml) 0.18 (0.06–0.31) 0.14 (0.03–0.62) 0.86 0.21 (0.08–0.32) 0.15 0.61
TG-Peak (nM) 217 (176–261) 236 (176–277) 0.42 227 (172–267) 199 0.62
TG-ttPeak (min) 10.0 (8.4–11.9) 9.1 (7.4–11.2) 0.26 9.8 (8.7–11.2) 9.7 0.87
TG-ETP (nM�min) 1222 (1056–1403) 1336 (1164–1471) 0.26 1271 (1118–1427) 1123 0.15
PPL (sec) 34.0 (28.4–40.2) 36.0 (29.4–41.2) 0.88 33.6 (28.0–39.8) 37.1 0.19
Total TF (a.u.) 4.8 (4.5–5.1) 5.1 (5.0–5.3) 0.03 4.8 (4.6–5.1) 4.8 0.92
IQR = Interquartile range; VTE = Venous thromboembolism.; EV-TF = Tissue factor associated with extracellular vesicles; TG = Thrombin generation; ttPeak = Time
to peak; ETP = Endogenous thrombin potential; PPL = Phospholipids; TF = Tissue factor; a.u. = Arbitrary units
aComparison of biomarker levels based on VTE incidence using Mann-Whitney test.
bDue to the limited number of patients in this subgroup data on IQR is not available.
https://doi.org/10.1371/journal.pone.0207387.t003
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Fig 3. Kaplan-Meier curve of overall survival based on TG-Peak at baseline (tertiles), for all patients and by disease
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We found a weak correlation between levels of total TF and EV-TF, which possibly relates
to differences between immunologic methods and coagulation activity assays. Further, previ-
ous studies showed that immunologic methods have different specificities and may include
non-specific binding [31,32]. TF can be in an active or in an inactive state depending on its
membrane phospholipid environment and status of a specific disulfide bond in the extracellu-
lar domain [33,34]. Immunoassays detect both active and inactive TF whereas EV-TF assays
detect only active TF.
Of potential interest, we found evidence of an association of TG-Peak with survival, and
EV-TF showed a weak association although neither of the biomarkers associated with VTE
Table 4. Mortality ratios vs biomarker levels at baseline, for all patients and by disease stage.
All patients Limited disease Extensive disease
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
EV-TF
Low 1.00 1.00 1.00
High 1.30 0.97–1.74 0.08 1.20 0.67–2.15 0.53 1.02 0.72–1.44 0.93
TG-Peak
Low 1.00 1.00 1.00
Intermediate 1.29 0.92–1.80 0.14 1.41 0.82–2.44 0.22 1.30 0.85–1.99 0.22
High 1.44 1.03–2.01 0.03 1.31 0.73–2.33 0.36 1.69 1.11–2.57 0.01
HR = Hazard Ratio; CI = Confidence interval; EV-TF = Tissue factor associated with extracellular vesicles; TG = Thrombin generation; Cut-offs: Upper quartile for
EV-TF and tertiles for TG-Peak.
https://doi.org/10.1371/journal.pone.0207387.t004
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Fig 4. Kaplan-Meier curve of the predictive values of baseline EV-TF (cut-off at the 75th percentile) on the effect of
LMWH on overall survival, for all patients and by disease extent.
https://doi.org/10.1371/journal.pone.0207387.g004
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risk. It may be speculated that this relates to the procoagulant signaling function of TF and
thrombin that can promote tumorigenesis via activation of protease-activated-receptors
(PARs) independently of clinically manifest VTE [35]. In this scenario, preferentially EV-asso-
ciated TF would execute the signaling function through PARs, resulting in e.g. increased
tumor angiogenesis [36]. Another finding of potential interest, was that low baseline EV-TF
predicted a negative effect of LMWH treatment on patient survival. With its pleiotropic inter-
actions, including coagulation factors, growth factors, and cytokines, the net effect of LMWH
is probably the sum of pro- and anti-tumorigenic activities, where the latter may include inhi-
bition of EV-TF dependent PAR activation [27,37].
Some limitations of our study should be noted. Firstly, few thrombotic events were regis-
tered, and VTE data need to be confirmed by further studies in independent cohorts. How-
ever, it may be concluded that there is no strong correlation between studied biomarkers and
VTE. Secondly, although patient samples were collected according to a well-defined study pro-
tocol and each coagulation assay was performed by the same qualified personnel, samples were
retrieved from many different sites with potential variations.
To conclude, we found no value of analyzed plasma coagulation biomarkers in the predic-
tion of VTE risk in SCLC, whereas data suggested a potential association between coagulation
activation and SCLC aggressiveness. Future studies are warranted, particularly focusing on
aspects of the coagulation system in the local tumor microenvironment of SCLC and how this
may correlate with VTE and patient outcome.
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